Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Goodwill & Intangibles (2016 - 2025)

IGC Pharma (IGC) has disclosed Goodwill & Intangibles for 14 consecutive years, with $1.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Goodwill & Intangibles rose 99.78% to $1.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $1.9 million, a 99.78% increase, with the full-year FY2025 number at $1.9 million, up 99.78% from a year prior.
  • Goodwill & Intangibles was $1.9 million for Q1 2025 at IGC Pharma, up from $1.7 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $1.9 million in Q1 2025 to a low of $226000.0 in Q1 2021.
  • A 5-year average of $842250.0 and a median of $603500.0 in 2022 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: surged 185.84% in 2022, then dropped 17.34% in 2023.
  • IGC Pharma's Goodwill & Intangibles stood at $272000.0 in 2021, then skyrocketed by 137.5% to $646000.0 in 2022, then decreased by 13.16% to $561000.0 in 2023, then surged by 206.6% to $1.7 million in 2024, then rose by 7.67% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Goodwill & Intangibles are $1.9 million (Q1 2025), $1.7 million (Q2 2024), and $927000.0 (Q1 2024).